Alan AU
GT Healthcare Group



Alan has over 20 years of experience across healthcare investment banking, private equity and venture capital investments in Asia/China. He is Managing Partner at GT Healthcare Capital Group, a private equity fund focusing on cross border healthcare investments founded in 2015.

Alan is currently a Board member and Audit Committee Chairman of CSPC Pharmaceutical Group (1093.hk, a Hang Seng Index constituent company), a leading pharmaceutical group in China. He is also a Board member of I-Mab Biopharma Group (Nasdaq: IMAB), a rapidly growing clinical-stage biopharmaceutical company. Besides, Alan serves as a panel member of the Innovation and Technology Fund of the Hong Kong SAR Government.

Alan was a Board member of Simcere Pharmaceutical Group (now 2096.hk; previously listed on NYSE: SCR and was privatized in 2013, when Mr. Au was Chairman of the Special Committee of the Board). He also served as a Board member of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in 2016). Besides, Alan was a Board member of Cellular Biomedicine Group (Nasdaq: CBMG, privatized in Feb 2021, when he was Chairman of the Special Committee of the Board).

Earlier in his career, Alan was Head of Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A mainly in Asia. Prior to that, he was Executive Director at JAFCO Asia Investment Group, responsible for healthcare investments in China; and Investment Director at Morningside Group, responsible for healthcare investments in Asia. Alan started his career at KPMG and KPMG Corporate Finance, where he was involved in regional M&A transactions and financial advisory services.

Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Mr. Au received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong, and a Master’s degree in Management from Columbia Business School in New York.